MENU ABOUT US MAKE A DONATION
The Epoch Times
Login
SEARCH
CLOSE
Help Center subscribe newsletter Newsstands Epoch Shop Gift
  • TOP NEWS
  • SPECIAL SERIES
  • SPECIAL COVERAGE
  • LATEST ARTICLES
  • US
    • US News
    • US Features
    • US Politics
    • US Crime News
    • New York
    • San Francisco
    • Los Angeles
  • Opinion
    • Thinking About China
    • Viewpoints
    • Unbridled Evil: The Corrupt Reign of Jiang Zemin in China
    • The Reader’s Turn
  • China News
    • US-China Relations
    • Chinese Regime
    • Business & Economy
    • Chinese Culture
    • China Human Rights
    • Social Issues
    • Organ Harvesting in China
  • World News
    • Africa News
    • Americas
    • Asia & Pacific
    • Canada
    • Europe
    • UK News
    • Australia News
    • International
    • Middle East
  • Business & Markets
    • Companies
    • Economy
    • Markets
    • Real Estate
    • Gold and Commodities
  • ARTS & CULTURE
    • Fine Arts & Craftsmanship
    • Performing Arts
    • Books
    • Traditional Culture
    • Shen Yun Special Coverage
    • Film & TV
  • Science
    • News
    • Space
    • Environment
  • Tech
    • Tech News
    • Tech Products & Reviews
    • Social Media
  • Sports
  • Videos
    • American Thought Leaders
    • China Insider
    • Crossroads
  • Bright
    • Lifestyle
    • Inspired
    • Family & Education
    • Personal Finance
    • American Essence
  • Entertainment
    • Film & TV
    • Entertainment News
  • Health
    • Experts
    • Conditions
    • Life & Wellness
  • Special Topics
    • Battlefields
SEARCH
  • EpochTV
  • US
  • US Politics
  • Opinion
  • World News
  • China
  • Hong Kong
  • Health
  • Bright
  • Arts
  • Falun Gong
  • Premium
  • Markets
  • Games
  • Livestream
  • More

Upside

  • Here’s Why DA Davidson Sees 59 Percent Upside in Roku
    Here’s Why DA Davidson Sees 59 Percent Upside in Roku
    DA Davidson analyst Tom Forte kept his Buy rating and $200 price target on Roku Inc.. The price target implied an upside of 59.3 percent. Forte recently held talks with Conrad Grodd, the company's ...
    March 24, 2022BY Benzinga
  • Tesla Bull Dan Ives Sees 70 Percent Upside in Tesla
    Tesla Bull Dan Ives Sees 70 Percent Upside in Tesla
    Tesla Inc. overcame a “major overhang” after German authorities cleared its production at a new factory in Berlin, ...
    March 8, 2022BY Benzinga
  • Wells Fargo Sees 67 Percent Upside in Samsara Post Q4 Results
    Wells Fargo Sees 67 Percent Upside in Samsara Post Q4 Results
    Wells Fargo analyst Michael Turrin on Thursday lowered the firm's price target on Samsara Inc. to $26 from $31 (67 percent ...
    March 6, 2022BY Benzinga
  • JPMorgan Sees Sharp Upside in Qualcomm, Thanks to Apple
    JPMorgan Sees Sharp Upside in Qualcomm, Thanks to Apple
    JPMorgan analyst Samik Chatterjee reiterated an Overweight rating on Qualcomm Inc. with a $225 price target, ahead of the company's fiscal Q1 ...
    February 2, 2022BY Benzinga
  • Here’s Why KeyBanc Sees 39 Percent Upside in Nutanix
    Here’s Why KeyBanc Sees 39 Percent Upside in Nutanix
    KeyBanc analyst Thomas Blakey initiated coverage of Nutanix Inc. with an Overweight rating and a $39 price target, suggesting an upside ...
    January 20, 2022BY Benzinga
  • B. Riley Sees Audacy’s Risk-Reward Profile Skewing Heavily to the Upside
    B. Riley Sees Audacy’s Risk-Reward Profile Skewing Heavily to the Upside
    B. Riley analyst Daniel Day upgraded Audacy Inc. to Buy from Neutral with a price target of $5, up from $4 ...
    December 17, 2021BY Benzinga
  • Goldman Sachs Adds This Software Technology Company to Conviction List With 58 Percent Upside Potential
    Goldman Sachs Adds This Software Technology Company to Conviction List With 58 Percent Upside Potential
    Goldman Sachs analyst Gabriela Borges initiated coverage of Qualtrics International Inc. with a Buy rating and a $53 ...
    December 14, 2021BY Benzinga
  • Goldman Sachs Sees Sharp Upside in HubSpot; Initiates Coverage With ‘Buy’ Rating
    Goldman Sachs Sees Sharp Upside in HubSpot; Initiates Coverage With ‘Buy’ Rating
    Goldman Sachs analyst Gabriela Borges initiated coverage of HubSpot Inc. with a Buy rating and $953 price target, ...
    December 14, 2021BY Benzinga
TOP NEWS
  • Trump Urges Netanyahu Not to Retaliate After Iran’s Missile Attack
    NEW By T.J. Muscaro
    Trump Urges Netanyahu Not to Retaliate After Iran’s Missile Attack
  • America in Photos: USS Iwo Jima Naval Homecoming, Belmont Stakes Horse Race, and Tiananmen Massacre Memorial
    NEW By Epoch Times Staff
    America in Photos: USS Iwo Jima Naval Homecoming, Belmont Stakes Horse Race, and Tiananmen Massacre Memorial
  • Trump on Iran Conflict: Troops Staying Until ‘We Have a Completion’
    4hr By T.J. Muscaro
    Trump on Iran Conflict: Troops Staying Until ‘We Have a Completion’
  • Iran Launches First Missiles at Israel Since Ceasefire Agreement
    5hr By Jacki Thrapp and T.J. Muscaro
    Iran Launches First Missiles at Israel Since Ceasefire Agreement
  • Israel Strikes Beirut Days After US-Supported Ceasefire Announcement
    6hr By Jack Phillips
    Israel Strikes Beirut Days After US-Supported Ceasefire Announcement
  • Former Utah Attorney General Fights the Evil That Lurks in Quiet Places
    7hr By Savannah Hulsey Pointer
    Former Utah Attorney General Fights the Evil That Lurks in Quiet Places
  • US Forces Shoot Down 2 Iranian Drones as Pakistani Interior Minister Visits Tehran
    9hr By Jacki Thrapp
    US Forces Shoot Down 2 Iranian Drones as Pakistani Interior Minister Visits Tehran
  • US Won’t Unfreeze Iran’s Assets Before Peace Deal Is Reached, Trump Says
    9hr By Jacki Thrapp
    US Won’t Unfreeze Iran’s Assets Before Peace Deal Is Reached, Trump Says
  • Fascia: The Living, Interconnected Web Behind Movement and Healing—How to Enhance Its Function
    10hr By Mercura Wang
    Fascia: The Living, Interconnected Web Behind Movement and Healing—How to Enhance Its Function
  • Eli Lilly Poised to Suspend Drug Discounts to Large Hospitals
    14hr By Lawrence Wilson
    Eli Lilly Poised to Suspend Drug Discounts to Large Hospitals
The Epoch Times
Copyright © 2000 - 2026 The Epoch Times Association Inc. All Rights Reserved.
Back Top